+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
MALE
ID07332455

Open-label Study to Evaluate GSK5471713 Dose and Safety in Adult Men With Metastatic Castration-Resistant Prostate Cancer

Led by GlaxoSmithKline · Updated on 2026-10-28

54

Participants Needed

20

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating GSK5471713 as a new treatment for adult men with metastatic castration-resistant prostate cancer mCRPC. This first-time-in-human study aims to assess the safety, tolerability, how the drug moves through and affects the body, and to understand the potential benefits and risks of using GSK5471713 alone in this advanced prostate cancer. Participants will receive GSK5471713 at different dose levels based on a dose escalation design to find the appropriate dose. The study is open-label and includes dose escalation and dose optimization phases. Treatment is given according to the assigned dose level, with monitoring for any dose limiting toxicities or adverse events throughout the study. During the trial, participants will be closely monitored for safety through tracking of side effects, serious adverse events, and any dose changes needed. Researchers will also measure blood levels of the drug and evaluate prostate cancer responses using prostate-specific antigen PSA levels and tumor response assessments. The study will last for approximately 45 months with ongoing assessments, safety monitoring, and evaluation of clinical activity.

CONDITIONS

Brief Title

First-Time-in-Human Study of GSK5471713 in Adults With mCRPC

Research Team

U

US GSK Clinical Trials Call Center

E

EU GSK Clinical Trials Call Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here